Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
Myomo, Inc. reported Q1 2026 revenue of $10.1 million, up about 3% from a year earlier, as higher average selling prices and international sales offset softer direct-to-patient volume. Gross margin improved to 68.2% from 67.2%, helped by pricing and lower material costs despite higher clinical expenses.
The company recorded a net loss of $3.0 million, narrowed from $3.5 million, and negative operating cash flow of $2.2 million. Adjusted EBITDA loss improved to $2.3 million from $2.8 million as operating expenses were roughly flat, with lower R&D and G&A partly offset by higher selling, clinical and marketing costs tied to advertising and new clinical sales staff.
Myomo ended the quarter with $15.7 million in cash, cash equivalents and short-term investments and working capital of $16.3 million. Long-term debt totaled $12.6 million under a Avenue term loan facility, whose derivative and warrant features produced a non-cash gain from a lower fair value. Management expects current liquidity to fund operations for at least 12 months while focusing on growing recurring MyoConnect and O&P channel revenues and reducing advertising-driven customer acquisition costs.
Myomo, Inc. reported first quarter 2026 revenue of $10.1 million, up 3% from a year earlier, driven by a higher average selling price and a growing mix of recurring patient sources, which rose to 49% of revenue versus 25% in the prior-year quarter.
Gross margin improved to 68.2% and operating expenses fell 1%, narrowing the net loss to $3.0 million, or $0.07 per share. Management expects second quarter 2026 revenue of $10.3 million to $10.8 million and reaffirmed full-year 2026 revenue guidance of $43 million to $46 million, citing a larger backlog and expanding in-network payer access.
Myomo, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held June 25, 2026. Stockholders will vote on electing two Class III directors, a non-binding advisory vote on executive compensation, ratifying CBIZ CPAs P.C. as auditor, approving Amendment No. 3 to the 2018 Stock Option and Incentive Plan to add 1,833,000 shares, and amending the certificate of incorporation to increase authorized common stock to 100,000,000 shares.
Only holders of record as of the record date, April 29, 2026, may vote. The board recommends voting FOR the director nominees, executive compensation, the auditor appointment, the plan amendment, and the charter amendment. Registration for the virtual meeting is at www.proxydocs.com/MYO by June 20, 2026.
Myomo, Inc. filed an amendment to its 2025 annual report to add detailed Part III disclosures and correct dates on executive certifications. The update focuses on board structure, committee responsibilities, executive and director compensation, stock ownership and related-party financing transactions, but does not modify previously reported financial results.
The filing describes a six-member classified board with a lead independent director, four standing committees, and a code of business conduct. It details 2025 pay for the CEO, CFO and Chief Medical Officer, including salary, RSUs and performance bonuses, and outlines severance and change-in-control protections. It also discloses major shareholders, insider participation in 2024 equity offerings and fees paid to external auditors.
FEBBO WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director William J. Febbo received an equity award covering 45,000 shares of Common Stock as compensation. The Form 4 shows this as a grant of restricted stock units under the company’s 2018 Stock Option and Incentive Plan, with no cash paid per share.
The RSUs vest in full on the first anniversary of the grant date, meaning the entire 45,000-unit award is scheduled to vest after one year if conditions are met. Following this award, Febbo reports beneficial ownership of 45,000 shares/units directly, reflecting a routine, compensation-related equity grant rather than an open‑market purchase or sale.
MYOMO, INC. director William J. Febbo filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing does not report any stock transactions or holdings, indicating it is primarily an administrative disclosure of his insider status.
Myomo, Inc. appointed William “Will” Febbo to its Board of Directors effective April 14, 2026, as a Class II director serving until the 2028 annual meeting, bringing over 30 years of experience in healthcare, financial services, and technology-driven businesses.
As a non-employee director, he was granted 45,000 restricted stock units (RSUs) that vest on the first anniversary of his appointment. He will also receive an annual cash retainer of $60,000 and an additional $85,000 per year in RSUs vesting quarterly. The company highlighted his prior leadership at OptimizeRx, where revenue expanded from $5 million to $92 million with a five-year CAGR of 41%, and his capital markets background as important additions to Myomo’s board.
GUDONIS PAUL R reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis received a grant of 16,666 shares of Common Stock in the form of Restricted Stock Units (RSUs). This award comes under a program allowing employees to forego 10% of their salary for three months in exchange for RSUs with a grant date fair value equal to 115% of the salary exchanged. The RSUs vest in full on July 9, 2026. After this grant, Gudonis directly holds 1,277,316 shares of the company’s common stock.
MYOMO, INC. Chief Financial Officer David A. Henry reported routine equity compensation and related tax withholding transactions in company stock. He received 12,500 Restricted Stock Units under a board-approved program where employees exchange 10% of three months of salary for RSUs valued at 115% of the salary given up. These RSUs vest in full on July 9, 2026. On April 13, 2026, 3,953 shares of common stock at $0.71 per share were disposed of solely to pay income taxes on restricted stock units that vested on April 12, 2026, pursuant to an irrevocable election made on December 11, 2025. Following these transactions, he directly holds 445,174 shares of Myomo common stock.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis acquired 19,395 shares of common stock through a grant of Restricted Stock Units (RSUs) with no cash paid per share. These RSUs were issued under a program allowing employees to exchange 10% of their salary for equity at a grant date fair value of 115% of the salary given up, covering three months of salary.
The RSUs from this grant vest in full on July 9, 2026. After this award, Gudonis directly holds a total of 1,280,045 shares of Myomo common stock, underscoring that this is primarily a compensation-related equity grant rather than an open‑market purchase.